Mikro Biyosistemler has been established at METU-Technopolis on 2015, as a spin-off from METU. The core product of the company is a liquid biopsy platform, which uses a simple blood sample for cancer diagnostics and cancer research. The microfluidic technology enables isolation and enumeration of Circulating Tumor Cells (CTC) from the blood samples of cancer patients. Mikro Biyosistemler also provides consultancy and fabrication services for companies and institutions on microfluidics.


To become a global player in the field of oncology by introducing innovative solutions to unmet needs.


To convert the know-how and the patented cutting-edge technology into commercial products to improve cancer identification and treatment.